PEspeaks

Nov 22, 2017
Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.
Nov 16, 2017
Pharmaceutical Executive
is spectacular science enough to guarantee success for new medicines?
Nov 16, 2017
Pharmaceutical Executive
If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
Nov 16, 2017
John Sattler offers some tips on engaging executive and professional recruiters.
Nov 16, 2017
Organizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.
Nov 07, 2017
A year after the Accelerated Access Review explored how to speed up adoption of innovation across the NHS in England, the UK Government has responded. Leela Barham reports.
Nov 07, 2017
Despite FDA approval of seven biosimilars through October 2017, only three have come to market, fueling concerns about the safety of switching patients to new therapies.
Nov 07, 2017
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.
Nov 06, 2017
Pharmaceutical Executive
Can health stakeholders be friends without being captives? Reflector reports.
Nov 06, 2017
From Applied Clinical Trials
Experts are proposing more limited clinical trials for follow-on therapies in some situations, particularly for critical oncology drugs and for highly targeted treatments for rare conditions. Jill Wechsler reports.
native1_300x100
lorem ipsum